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Abstract: Lactobacillus fermentum UCO-979C (Lf979C) beneficially modulates the cytokine response
of gastric epithelial cells and macrophages after Helicobacter pylori infection in vitro. Nevertheless,
no in vivo studies were performed with this strain to confirm its beneficial immunomodulatory
e↵ects. This work evaluated whether Lf979C improves protection against H. pylori infection in mice
by modulating the innate immune response. In addition, we evaluated whether its exopolysaccharide
(EPS) was involved in its beneficial e↵ects. Lf979C significantly reduced TNF-↵, IL-8, and MCP-1
and augmented IFN-  and IL-10 in the gastric mucosa of H. pylori-infected mice. The di↵erential
cytokine profile induced by Lf979C in H. pylori-infected mice correlated with an improved reduction
in the pathogen gastric colonization and protection against inflammatory damage. The purified EPS
of Lf979C reduced IL-8 and enhanced IL-10 levels in the gastric mucosa of infected mice, while no
e↵ect was observed for IFN- . This work demonstrates for the first time the in vivo ability of Lf979C
to increase resistance against H. pylori infection by modulating the gastric innate immune response.
In addition, we advanced knowledge of the mechanisms involved in the beneficial e↵ects of Lf979C
by demonstrating that its EPS is partially responsible for its immunomodulatory e↵ect.
Keywords: Lactobacillus fermentum UCO-979C; exopolysaccharide; H. pylori; gastric
cytokines; immunobiotics
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1. Introduction
Helicobacter pylori (H. pylori) colonizes around 50% of the world population. This bacterium
is able to dominate the gastric microbiota and lead to gastric inflammation (gastritis) in infected
individuals [1,2]. The conventional treatment for H. pylori infection involves the combination of two
antibiotics (amoxicillin/clarithromycin) and a proton pump inhibitor. Although this therapy has been
useful in reducing the pathologies associated with H. pylori, its high cost, patient non-adherence to
treatment, and the appearance of resistant strains, have led to the search for new innocuous, natural
and healthier options, such as probiotics or plant derivatives [3–5].
In recent years, the scientific advances in probiotics have demonstrated their ability to improve
resistance against infectious diseases including those produced by gastrointestinal, respiratory and
urinary pathogens [6–8]. As probiotics have been proven to restore the microbiota balance, inhibit
pathogen’s growth and/or modulate mucosal immune responses, these microorganisms have been
widely used in the development of functional foods aiming to improve resistance against bacterial and
viral pathogens [8–10]. For this reason, the research interest in the characterization of new probiotic
strains with outstanding benefits on human health has been increased in recent years [11].
It is recognized that the gastric microbial community and the mucosal immune responses
determine the outcome of H. pylori infection [12]. Alterations in the microbiota and deregulation of the
inflammatory response during H. pylori infection can led to the development of important diseases such
as peptic ulcer-, gastric cancer- and mucosa-associated lymphoid tissue (MALT) lymphoma [1,2]. Thus,
probiotics have appeared as an alternative to modulate stomach microbiota and/or gastric inflammation
and to reduce the severity and complications of H. pylori infection [13,14]. In this regard, our previous
studies demonstrated the benefits of Lactobacillus fermentum UCO-979C against the pathogenic bacteria
H. pylori, which were related to its capability of forming biofilms [15]. L. fermentum UCO-979C inhibited
bacterial growth, reduced H. pylori urease activity, decreased pathogen adhesion to human gastric
epithelial cells and beneficially regulated the inflammatory response in in vitro model by reducing the
inflammatory chemokine IL-8 [16]. Besides, L. fermentum UCO-979C was able to di↵erentially modulate
the production of TNF-↵, IFN-  and IL-10 by gastric epithelial cells and macrophages, which may o↵er
advantages in the protection against H. pylori infection by improving the clearance of the pathogen
and the protection against inflammatory damage [17]. Futher in vitro studies demonstrated that the
UCO-979C strain is a remarkable immunomodulatory agent due to its ability to di↵erentially modulate
the immune response triggered by Toll- like receptor 4 (TLR4) activation through the modulation of
TLR negative regulators’ expression in epithelial cells [18].
Our previous studies with L. fermentum UCO-979C indicated the potential of this immunobiotic
strain to beneficially modulate the immune response to H. pylori infection. However, the molecules
of the UCO-979C strain involved in its immunomodulatory e↵ect were not investigated in detail.
Moreover, the ability of L. fermentum UCO-979C to modulate the immune response against the gastric
infection in vivo has not been evaluated before. Therefore, the aim of this work was to evaluate the
e↵ect of L. fermentum UCO-979C or its secreted exopolysaccharide (EPS) on the immune response
triggered by the pathogenic bacteria H. pylori in vitro and in vivo in a mouse model.
2. Materials and Methods
2.1. Microorganisms
L. fermentum UCO-979C [16] was obtained from the Bacterial Pathogenicity Laboratory culture
collection at University of Concepción (Concepción, Chile). L. fermentum CRL973 was obtained from
the CERELA-CONICET culture collection (Tucumán, Argentina). Lactobacilli strains were grown in
Mann–Rogosa–Sharpe Agar (MRS) (Difco, Lawrence, KS, USA) at 37  C. After an overnight growth,
bacteria were transferred to MRS broth and cultured at 37  C until stationary phase [15–17]. Afterwards,
the bacteria were pelleted (3000⇥ g for 10 min), washed twice with phosphate-bu↵ered saline (PBS)
and suspended in specific media for in vivo or in vitro assays.
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Commercially available H. pylori ATCC43504 (American Type Culture Collection, Manassas, VA,
USA) and a mouse-adapted strain H. pylori SS1 [19] were used for cell culture assays and to induce
gastric infection in mice, respectively. Both strains were obtained from the Bacterial Pathogenicity
Laboratory culture collection at University of Concepción (Concepción, Chile). Bacteria were cultured
on Columbia blood agar base (Oxoid, Hampshire, UK) supplemented with 5% horse blood and
antibiotics (supplement DENT, Oxoid, Hampshire, UK) in a microaerobic atmosphere (10% CO2,
5% O2, 85% N2) at 37  C for 72 h. The growth form the entire plate was washed twice with PBS and
suspended in PBS enriched with 5% of horse serum (GE Healthcare, Chicago, IL, USA).
2.2. Exopolysaccharide Extraction
The secreted EPS was isolated according to Ferrer et al. [20] with slight modifications. Briefly,
a chemical-defined medium (CDM) was inoculated with (2% v/v) of an overnight culture of selected
lactobacilli (grown as referred in Section 2.1) and incubated for 24 h at 37  C under microaerobic
conditions. After incubation, media were centrifuged (10,000⇥ g, 30 min, at 4  C) and the supernatant
treated with trichloroacetic acid (Winkler, Chile) (final concentration 15% v/v) for 2 h under agitation.
Then, proteins were precipitated by centrifugation (10,000⇥ g for 30 min, at 4  C) and the supernatant
was mixed with 2 volumes of absolute cold ethanol (Merck, Darmstadt, Germany) followed by an
overnight incubation at 4  C, to enhance the EPS precipitation. Finally, the EPS was harvested by
centrifugation (10,000⇥ g, 30 min, at 4  C) and the pellet was dissolved in distilled water (1/10 of
the original volume), dialyzed at 4  C by using dialysis membranes (14 kDa cut-o↵, Sigma Aldrich,
St. Louis, MO, USA) and finally lyophilized [20]. For in vivo and in vitro assays, the dried EPS was
suspended in PBS.
2.3. Cell Lines
Human gastric adenocarcinoma epithelial cells (AGS, ATCC CRL1739) were provided by the
Bacterial Pathogenicity Laboratory, Department of Microbiology, University of Concepción (Concepción,
Chile). Activation, propagation and freezing were carried out according to protocol for AGS cells
(https://www.atcc.org/products/all/CRL-1739). AGS cells were cultured and handled according to
Garcia-Castillo et al. (2018) [17]. After incubation, cells (1 ⇥ 105 cells/mL) in a flat-bottom 24-well were
washed with warmed PBS, and fresh culture media without antibiotics was added.
The human monocytic leukemia (THP-1) cell line was provided by the Department of Clinical
Biochemistry and Immunology, University of Concepción (Concepción, Chile). Activation, propagation
and freezing were carried out according to protocol for THP-1 cells (https://www.atcc.org/products/
all/TIB-202). For assays, THP-1 cells were handled according to Garcia-Castillo et al. [17]. Cells were
maintained in RPMI-1640 medium (Gibco) supplemented with 10% v/v of heat-inactivated fetal bovine
serum (SFB) (Biological Industries, Cromwell, CT, USA), 100 U/mL of penicillin, and 100 µg/mL of
streptomycin (Corning). THP-1 cells (1 ⇥ 105 cells/mL) were incubated with 200 nM of PMA (Phorbol
12-Myristate 13-Acetate) for 24 h, to induce the di↵erentiation of monocytes into macrophages. For
immunomodulation assays, cells were washed and fresh culture media without antibiotics was added.
2.4. E↵ect of EPS on H. pylori Adhesion to AGS Cells
The e↵ect of EPSs isolated from L. fermentum UCO-979C or L. fermentum CRL973 on the adhesion of
H. pylori ATCC 43,504 to AGS cells was evaluated as previously described by Garcia-Castillo et al. [17]
with modifications. Briefly, AGS cells were co-incubated with 100 µg/mL of UCO-979C EPS or
CRL973 EPS for 24 h before the challenge with 107 CFU/mL of H. pylori ATCC43504 for other
24 h. After incubation, AGS cells were washed and detached with 300 µL of Trypsin/EDTA 0.05%
(Corning, Manassas, VA, USA), then 700 µL of DMEM without antibiotics was added. Suspension was
homogenized and 10-fold dilution series were performed in PBS. Serial dilutions of the bacteria/cell
suspension were seeded in selective Columbia agar plates. AGS cells infected with H. pylori without
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prophylactic treatment were considered as 100% adhesion. The UCO-979C EPS concentration was
selected by preliminary experiments.
2.5. E↵ect of EPS on AGS and THP-1 Cells Cytokines Profiles
In order to evaluate the e↵ect of EPSs on the innate immune response, AGS cells or THP-1
di↵erentiated macrophages were incubated with 100 µg/mL UCO-979C EPS or CRL973 EPS for 24 h,
and supernatants were collected for cytokines analysis. Cells without EPS stimulation were used as
basal controls.
The e↵ect of UCO-979C EPS or CRL973 EPS in the cytokine response to H. pylori infection was
also evaluated. AGS cells or THP-1 di↵erentiated macrophages were incubated with 100 µg/mL of
UCO-979C EPS or CRL973 EPS and then challenged with 107 CFU/mL of H. pylori ATCC43504 for
24 h. Cells without EPS stimulation and infected with H. pylori were used as infected controls. After
incubation, supernatants were collected and kept at  80  C to determined cytokines and chemokines by
ELISA (DuoSet R&D Systems, Minneapolis, MN, USA). The levels of TNF-↵, IL-6 and IL-8, and MCP-1
(pg/mL) were determined in the supernatant of AGS cells. The levels of TNF-↵, IL-6, IL-10 and IFN- 
(pg/mL) were determined in the supernatant of THP-1 cells.
2.6. Animals and Experimental Infection
Female adult Swiss (6-week-old) SPF (specific pathogen free) mice were obtained from the closed
colony kept at CERELA-CONICET (Tucuman, Argentina). They were housed in plastic cages with
controlled room temperature (22 ± 2  C temperature, 55 ± 2% humidity) and were fed ad libitum with
a conventional balanced diet. Animal welfare was ensured by researchers and special trained sta↵ in
animal care and handling at CERELA-CONICET. Animal health and behavior were monitored twice a
day. This study was carried out in strict accordance with the recommendations in the Guide for the
Care and Use of Laboratory Animals of the Guidelines for Animal Experimentation of CERELA. The
CERELA Institutional Animal Care and Use Committee prospectively approved this research under
the protocol BIOT-CRL-IBT18.
Mice were treated with viable L. fermentum UCO-979C or L. fermentum CRL973 or their EPSs.
Viable bacteria were administered on two consecutive days at a daily dose of 108 CFU/mouse. Bacteria
were suspended in 5 mL of 10% skimmed milk and added to the drinking water and the consumption
was monitored ensuring each mouse drinks 5–6 mL per day. Lactobacilli viability in drinking water
was assessed after 24 h by plating in MRS and Bactlight® viability kit (Thermofisher, Buenos Aires,
Argentina). UCO-979C EPS or CRL973 EPS were administered by drinking water at a concentration
of 100 µg/mL for two consecutive days. The infection control only received water instead probiotic
or EPS suspension. After two days of lactobacilli or EPSs administration, these mice and untreated
controls were infected with H. pylori SS1 using 100 µL of 6 ⇥ 108 CFU/mL of the pathogenic strain by
gavage [21]. Mice were housed individually during the experiments and the assays for each parameter
studied were performed in 5–6 mice per group. Two days post-infection (dpi), blood samples were
collected in heparinized tubes by cardiac puncture under anesthesia. Afterwards, the stomachs were
removed and processed for histological and immunological examination. To assess the gastric damage
after H. pylori infection, stomachs were fixed in 4% (v/v) formalin saline solution, then dehydrated and
embedded in para n wax (Leica Microsystems, Mannheim, Germany). Samples were cut in sections
and stained with hematoxylin-eosin. Blind microscopic examination of slides was performed.
2.7. Adhesion of H. pylori to Mouse Gastric Mucosa
In order to evaluate the H. pylori adhesion in presence or absence of lactobacilli or EPS, stomachs
were aseptically excised, weighed and dissected. Each stomach was placed in BHI broth, homogenized
and diluted in PBS (10 fold). Then, dilutions were seeded on selected agar media for H. pylori and
incubated for 72 h at 37  C under microaerobic conditions [22]. H. pylori presence was confirmed by
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Gram staining and positive urease activity, and the concentration was expressed as CFU per gram
of stomach.
Urease activity was determined in processed stomachs by a modified version of red phenol
method [23,24]. Briefly, stomach samples were placed in a solution containing 0.002% of phenol red,
urea 150 and 100 mM phosphate bu↵er and urease activity was measured by absorbance (570 nm) after
2 h by using Infinite M200 pro (TECAN) plate reader. H. pylori SS1-infected group mean absorbance
was considered as 100% of urease activity.
2.8. Gastric and Serum Immunological Response
For evaluating the e↵ect of the prophylactic administration of lactobacilli or their EPSs on the
inflammatory response, cytokines and chemokines were measured. Briefly, stomachs from mice were
individually grounded in a mortar with cold 5 mL of PBS and centrifuged [25,26]. Supernatant was
collected and stored at  80  C until cytokine/chemokine determination. Cytokines (IFN- , IL-10,
TNF-↵) and chemokines (IL-8, MCP-1) were quantified by enzyme-linked immunosorbent assay
(ELISA) kits, following the manufacturer’s recommendations (DuoSet R&D Systems, Minneapolis,
MN, USA). The values were expressed as pg per gram of stomach. In addition, to evaluate the e↵ect
of lactobacilli and EPSs treatments and infection on the systemic immune response, blood samples
from mice were collected in heparinized tubes by cardiac puncture. Mouse serum samples were kept
at  80  C until cytokine/chemokine determination by ELISA kits. Values were expressed as pg/mL
of serum.
2.9. Statistical Analysis
Experiments were performed in triplicate and results were expressed as mean± standard deviation.
After verification of the normal distribution of data, 2-way ANOVA was used. Tukey’s test (for pairwise
comparisons of the means) was used to test for di↵erences between the groups. Di↵erences were
considered significant at p < 0.05 or p < 0.01.
3. Results
3.1. L. fermentum UCO-979C Improves the Resistance Against H. pylori Infection in Mice
Our previous in vitro studies have clearly demonstrated the ability of L. fermentum UCO-979C to
inhibit H. pylori growth and adhesion to human gastric epithelial cells [15] and to beneficially regulate
the inflammatory response triggered by the pathogen in both epithelial cells and macrophages [17]. In
this work, in a first set of experiments, we aimed to confirm the immunomodulatory and anti-H. pylori
e↵ects of L. fermentum UCO-979C in an in vivo animal model. For this purpose, adult immunocompetent
mice were treated with the UCO-979 strain, as described in detail in materials and methods, and then
challenged with H. pylori. The non-immunomodulatory strain L. fermentum CRL973 [18] was used
for comparison. As shown in Figure 1, mice treated with L. fermentum UCO-979C had lower H. pylori
colony counts associated with the stomachs, as well as reduced urease activity when compared to the
control group. On the contrary, L. fermentum CRL973 was not able to modify the levels of H. pylori
colonization when compared to control mice. Although the urease activity in CRL973-treated mice
was lower than the observed in the H. pylori- infected control group, it was significantly higher when
compared to that observed in UCO-979C-treated animals (Figure 1).
Histopathological analysis of stomach tissue sections was performed in the di↵erent groups of mice
in order to evaluate the tissue damage and the inflammatory response (Figure 2). The infection of adult
immunocompetent mice with H. pylori significantly increased the inflammatory cells infiltrating the
stomach mucosa, since control mice displayed no inflammation versus notable inflammatory changes
in the infected control mice. Inflammatory infiltrates consisted of neutrophils and mononuclear cells in
the lamina propria and around the gastric glands, as has been described in previous publications [27,28].
The inflammation of gastric tissue in L. fermentum UCO-979C-treated mice was milder than that in
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controls after infection. There were only mild inflammatory neutrophil and mononuclear-cell infiltrates
in the UCO-979C group (Figure 2). On the other hand, L. fermentum CRL973-treated mice showed
neutrophil and mononuclear-cell infiltration in the gastric tissue that were not di↵erent from infected
controls (Figure 2).
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Figure 1. E↵ect of viable L. fermentum UCO-979C or L. fermentum CRL973 on gastric colonization of
H. pylori SS1. L. fermentum UCO-979C or L. fermentum CRL973 were administered to di↵erent groups
of mice for two consecutive days at a dose of 108 UFC/mouse/day, then mice were challenged with
H. pylori SS1. Two days post-infection, mice were euthanized. H. pylori counts (Log CFU/g of tissue)
and Urease activity (% percentage) were determined in gastric explants. Mice infected with H. pylori
were used as controls. The results represent three independent experiments and are expressed as mean
± SD. Significant di↵erences when compared to the control group: * (p < 0.05),** (p < 0.01). Significant
di↵erences when compared to the indicated group: † ( 0.05).Microorganisms 2020, 8, x FOR PEER REVIEW 7 of 21 
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Figure 2. E↵ect of viable L. fermentum UCO-979C or L. fermentum CRL973 in the gastric inflammatory
response of competent adult mice infected with H. pylori SS1. L. fermentum UCO-979C or L. fermentum
CRL973 were administered to di↵erent groups of mice for two consecutive days at a dose of 108
CFU/mouse/day, then mice were challenged with H. pylori SS1. Two days post-infection, mice were
euthanized, and histopathological evaluation of gastric samples was performed. Hematoxilin/eosin
stained sections of gastric mucosa. Upper left: Normal appearance of mice gastric mucosa. Upper
right: Control group: Swiss mice infected with H. pylori. Lo er left: L. fermentum UCO-979-H. pylori
group. Lower right: L. fermentum CRL 973-H. pylori gr . riginal magnification 200⇥.
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3.2. L. fermentum UCO-979C Di↵erentially Modulates the Immune Response Against H. pylori Infection
in Mice
Cytokines and chemokines were measured in the stomach (Figure 3) and serum (Figure 4) samples
of lactobacilli-treated and untreated control groups after the challenge with H. pylori. The infection of
adult immunocompetent mice with H. pylori significantly increased the levels of the inflammatory
factors IFN- , TNF-↵, MCP-1 and IL-8, as well as the levels of the regulatory cytokine IL-10 when
compared to basal levels in non-infected animals (data not shown). Mice treated with L. fermentum
UCO-979C had significantly higher levels of gastric and serum IFN-  when compared to the control
group (Figures 3 and 4). On the contrary, the UCO-979C-treated group showed significantly lower levels
of gastric and serum TNF-↵ and IL-8 compared to the control group (Figures 3 and 4). L. fermentum
UCO-979C was also able to reduce the levels of MCP-1 in the gastric mucosa when compared to
controls (Figure 3). In addition to its ability to diminish inflammatory cytokines and chemokines,
it was observed that the UCO-979C strain was capable of inducing a significant increase in IL-10 levels
when compared to controls in both the gastric mucosa (Figure 3) and serum (Figure 4). The group
of animals treated with L. fermentum CRL973 did not exhibit any variation in gastric IFN- , IL-10,
TNF-↵, MCP-1 levels and only gastric IL-8 values were lower than that observed in the control group
(Figure 3). On serum samples, there were not statistically significant di↵erences between L. fermentum
CRL973 and control mice (Figure 4).
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Figure 4. E↵ect of viable L. fermentum UCO-979C or L. fermentum CRL973 on serum cytokines in adult
immunocompetent mice infected with H. pylori SS1. L. fermentum UCO-979C or L. fermentum CRL973
were administered to di↵erent groups of mice for two consecutive days at a dose of 108 CFU/mouse/day,
then mice were challenged with H. pylori SS1. Two days post-infection, serum concentrations of IFN- ,
IL-10, TNF-↵, IL-8 and MCP-1 (pg/mL) were determined. Mice infected with H. pylori were used as
controls. Results are expressed as mean ± SD. Significant di↵erences when compared to the control
group: * (p < 0.05). Significant di↵erences when compared to the indicated group: † (p < 0.05).
3.3. The EPS from L. Fermentum UCO-979C Reduces H. pylori Adhesion to AGS Cells
In a second set of experiments, we evaluated whether the EPS produced by L. fermentum strain
UCO-979C was involved in the in vitro and in vivo abilities to improve resistance against H. pylori and
di↵erentially modulate the immune response. We first evaluated the ability of the EPS produced by the
UCO-979C to modify the adhesion of H. pylori to AGS cells. For this purpose, AGS cells were treated
with UCO-979C EPS prior to H. pylori infection. The EPS isolated from strain L. fermentum CRL973
was used for comparison. As shown in Figure 5, both UCO-979C EPS and CRL973 EPS significantly
reduced H. pylori adherence. However, the protective e↵ect of UCO-979C EPS was greater than that for
CRL973 EPS (Figure 5).
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Figure 5. E↵ect of Lactobacillus fermentum UCO-979C EPS pre-incubation on Helicobacter pylori adhesion
to human gastric epithelial cells (AGS cells) challenged with H. pylori AGS cells were stimulated
with EPS-979C or EPS-973 for 24 h before the challenge. Results are expressed in percentage, 100%
correspond to infected control and represent data from three independent experiments. Results are
expressed as mean ± SD. Significant di↵erences when compared to the control group: * (p < 0.05),
** (p < 0.01). Significant di↵erences when compared to the indicated group: † (p < 0.05).
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3.4. The EPS from L. fermentum UCO-979C Modulates Cytokine Profile in AGS and THP-1 Cells
We next aimed to evaluate whether the EPS produced by the probiotic strain L. fermentum
UCO-979C was able to modify the production of cytokines and chemokines in human gastric epithelial
cells and macrophages. AGS cells were stimulated with UCO-979C EPS and the levels of TNF-↵, IL-6
and IL-8 were measured in culture supernatants (Figure 6). Again, the EPS isolated from L. fermentum
CRL973 was used for comparison. The levels of TNF-↵ and IL-6 were significantly increased in the
presence of UCO-979C EPS or CRL973 EPS. However, CRL973 EPS was more e cient than UCO-979C
EPS to enhance TNF-↵ production in epithelial cells. On the contrary, IL-8 levels were not a↵ected by
UCO-979C EPS or CRL973 EPS treatments (Figure 6).
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When the e↵ect of EPSs on THP-1 cells was analyzed, it was observed that both UCO-979C EPS
and CRL973 EPS significantly increased the levels of IL-6 and IL-10 (Figure 7). However, UCO-979C
EPS was more e cient than CRL973 EPS to enhance IL-10 production in macrophages. The levels of
TNF-↵ were not a↵ected by UCO-979C EPS or CRL973 EPS treatments, while only the EPS produced
by the probiotic strain L. fermentum UCO-979C was able to increase the production of IFN-  (Figure 7).
We also evaluated whether the EPS of L. fermentum UCO-979C was able to modify the production
of cytokines and chemokines in human gastric epithelial cells and macrophages in the context of
H. pylori infection. It was observed that after the infection with H. pylori, secretion of TNF-↵, IL-6
and IL-8 increased considerably in AGS cells (Figure 8) compared to basal levels (Figure 6). Likewise,
TNF-↵, IL-6, IFN-  and IL-10 significantly increased in THP-1 cells (Figure 9) when compared to basal
levels (Figure 7).
AGS cells stimulated with UCO-979C EPS showed a significant decrease in the levels of the
inflammatory cytokines TNF-↵, IL-6 and IL-8 when compared with H. pylori-infected controls (Figure 8).
In addition, it was observed that the levels of TNF-↵ and IL-8 decreased significantly in AGS cell
treated with CRL973 EPS than in the control group (Figure 8). However, it should be noted that TNF-↵
was significantly lower in UCO-979C EPS-treated AGS cells than in those stimulated with CRL973 EPS.
On the other hand, the treatment of THP-1 cells with UCO-979C EPS previous to infection with
H. pylori did not exert any e↵ect on the levels of IFN-  and IL-10, since the concentrations of both
cytokines were not di↵erent from the control infected THP-1 cells (Figure 9). In addition, a modest
but significant decrease in the levels of TNF-↵ and IL-6 was observed in THP-1 cells treated with
UCO-979C EPS when compared to the infected controls (Figure 9). There were not statistical di↵erences
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in the levels of TNF-↵, IL-6, IFN-  or IL-10 when cells treated with the EPS from L. fermentum CRL973
and infected control cells were compared (Figure 9).
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Figure 7. E↵ect of Lactobacillus fermentum UCO-979C or L. fermentum CRL973 EPS on cytokine and
chemokine production of human macrophages (THP-1 cells). THP-1 cells were incubated with
100 µg/mL of L. fermentum UCO-979C or L. fermentum CRL973 EPS. The levels of TNF-↵, IL-6, IFN-  and
IL-10 (pg/mL) in culture supernatants were determined 24 h after stimulation. The results represent data
from three independent experiments. Results are expressed as mean ± standard deviation. Significant
di↵erences when compared to the control group: * (p < 0.05), ** (p < 0.01). Significant di↵erences when
compared to the indicated group: † (p < 0.05).
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Figure 8. E↵ect of Lactobacillus fermentum UCO-979C or L. fermentum CRL973 EPS on the cytokine and
chemokine production of human gastric epithelial cells (AGS cells) after Helicobacter pylori challenge.
AGS cells were incubated with 100 µg/mL of L. fermentum UCO-979C or L. fermentum CRL973 EPS for
24 h. Then, cells were challenged with H. pylori 43504. The levels of TNF-↵, IL-6, IFN-  and IL-10
(pg/mL) in culture supernatants were determined 24 h after infection. Results represent data from three
independent experiments. Results are expressed as mean ± standard deviation. Significant di↵erences
when compared to the control group: * (p < 0.05), ** (p < 0.01). Significant di↵erences when compared
to the indicated group: † (p < 0.05).
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but significant decrease in the levels of TNF-α and IL-6 was observed in THP-1 cells treated with 
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differences in the levels of TNF-α, IL-6, IFN-γ or IL-10 when cells treated with the EPS from L. 
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3.5. The EPS from L. fermentum UCO-979C Modulates the Inflammatory Response Triggered by H. pylori 
Infection in Mice 
Finally, we aimed to determine whether the EPS from L. fermentum UCO-979C was able to exert 
beneficial effects in vivo. For this purpose, mice were orally treated with an aqueous suspension of 
the lyophilized UCO-979C EPS and then challenged with H. pylori. Mice treated with CRL973 EPS 
Figure 9. E↵ect of Lactobacillus fermentum UCO-979C or L. fermentum CRL973 EPS on cytokine and
chemokine production of human macrophages (THP-1 cells) after Helicobacter pylori challenge. THP-1
cells were incubated with 100 µg/mL of L. fermentum UCO-979C or L. fermentum CRL973 EPS for 24 h.
Then, cells were challenged with H. pylori 43504. The levels of TNF-↵, IL-6, IFN-  and IL-10 (pg/mL)
in culture supernatants were determined 24 h after infection. The results represent data from three
independent experiments. Results are expressed as mean ± standard deviation. Significant di↵erences
when compared to the control group: * (p < 0.05), ** (p < 0.01). Significant di↵erences when compared
to the indicated group: † (p < 0.05).
3.5. The EPS from L. fermentum UCO-979C Modulates the Inflammatory Response Triggered by H. pylori
Infection in Mice
Finally, we aimed to determine whether the EPS from L. fermentum UCO-979C was able to exert
beneficial e↵ects in vivo. For this purpose, mice were orally treated with an aqueous suspension of
the lyophilized UCO-979C EPS and then challenged with H. pylori. Mice treated with CRL973 EPS
were used for comparisons. As shown in Figure 10, it was observed that the treatment of mice with
UCO-979C EPS did not induce significant di↵erences in the counting of pathogenic bacteria in stomach
samples. However, a significant reduction in the urease activity in UCO-979C EPS mice was detected
when compared to controls (Figure 10). As expected, there were not statistical di↵erences in H. pylori
counts or urease activity when mice treated with the EPS from L. fermentum CRL973 and infected
controls were compared (Figure 10).
In order to determine the impact of UCO-979C EPS on the innate immune response, we measured
gastric (Figure 11) and systemic (Figure 12) cytokines and chemokines in infected mice. It was observed
that the administration of UCO-979C EPS was capable of reducing the levels of serum and gastric
IL-8 as well as serum TNF-↵ in H. pylori-infected mice. In addition, UCO-979C EPS-treated mice had
significantly higher levels of gastric (Figure 11) and serum (Figure 12) IL-10 than infected controls. No
di↵erences were detected in the levels of IFN-  and MCP-1 when UCO-979C EPS and control mice
were compared. The CRL973 EPS did not exert any significant e↵ects in the levels of gastric or serum
cytokines and chemokines during H. pylori infection (Figures 11 and 12).
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Figure 10. E↵ect of L. fermentum UCO-979C or L. fermentum CRL973 EPS on gastric colonization of H.
pylori SS1. L. fermentum UCO-979C or L. fermentum CRL973 EPS were administered to di↵erent groups
of mice for two consecutive days at a dose of 108 100µg/mL/mouse/day, then mice were challenged with
H. pylori SS1. Two days post-infection, mice were euthanized, H. pylori counts (Log CFU/g of tissue) and
Urease activity (% percentage) were determined in gastric explants. Mice infected with H. pylori were
used as controls. Results are expressed as mean ± standard deviation. Significant di↵erences when
compared to the control group: * (p < 0.05). Significant di↵erences when compared to the indicated
group: † (p < 0.05).Microorganisms 2020, 8, x FOR PEER REVIEW 14 of 21 
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Figure 11. E↵ect of L. fermentum UCO-979C or L. fermentum CRL973 EPS on gastric cytokines and
chemokines in adult immunoco petent mice infect d with H. pylori SS1. L. fermen um UCO-979C or
L. fermentum CRL973 EPS were administered to di↵erent groups of mice for two co secutive days at a
dose of 100µg/m mouse/day, then mice w re challenged with H. pylori SS1. T day post-infection,
gastric c ncentrations of IFN- , IL-10, TNF-↵, IL-8 and MCP-1 (pg/mL) were determined. Mice infected
with H. pylori were us d as c tr ls. Results are expressed as mean ± standard deviation. Significant
di↵erenc s when compared to the control group: * (p < 0.05). Significant di↵er nce when comp red to
the indicated group: † (p < 0.05).
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Figure 12. E↵ect of L. fermentum UCO-979C or L. fermentum CRL973 EPS on serum cytokines and
chemokines in adult immunocompetent mice infected with H. pylori SS1. L. fermentum UCO-979C or
L. fermentum CRL973 EPS were administered to di↵er nt gro ps of mice for two consecutive day at a
dose of 100 µg/mL mouse/day, then mice were challenged with H. pylori SS1. Two days post-infection,
serum concentrations of IFN- , IL-10, TNF-↵, IL-8 and MCP-1 (pg/mL) were de ermined. Mice infected
with H. pylori were used as controls. Results are expressed as mean ± standard deviation. Significant
di↵erences when compared to the control group: * (p < 0.05). Significant di↵erences when compared to
the indicated group: † (p < 0.05).
4. Discussion
H. pylori triggers mucosal and systemic immune responses in infected individuals. However,
these immune responses are not always e cient for eradicating the pathogen [29,30]. Moreover,
the aggressive and persistent proinflammatory response induced by this pathogen can contribute to
the development of gastritis, preceding a series of morphological changes that may lead to gastric
cancer. An enhanced modification in DNA methylation in the gastric mucosa, which is considered as a
preliminary stage of tumor transformation, has been reported after H. pylori infection [31]. Moreover,
the infection-associated inflammatory response rather than H. pylori itself has been associated to
DNA methylation [31,32]. Then, mediators of inflammation including cytokines and chemokines,
are considered as important therapeutic targets to prevent gastritis and gastric cancer associated to
H. pylori infection [33]. In this regard, the beneficial e↵ect of probiotics for the protection against
H. pylori infection and inflammation is supported by a large amount of scientific evidence [13,14,34].
Earlier studies reported that L. salivarius WB 1004 [35], L. rhamnosus R0011 and L. acidophilus R0052 [36]
were able to di↵erentially modulate immune responses and diminish H. pylori colonization in mice.
The beneficial modulation of the inflammatory immune response and the reduction of H. pylori
adhesion has been also reported in in vitro experiments for probiotic strains such as L. bulgaricus [37]
and L. rhamnosus UCO-25A [38]. Moreover, studies have proposed the inactivation of Smad7 and
NF-B signaling pathways [39] and the activation of SOCS-2/SOCS-3 signaling through STAT1/STAT3
activation and JAK2 inactivation [40] as the molecular mechanisms of action for the beneficial e↵ects of
probiotics. Then, these and other in vitro and in vivo studies have clearly demonstrated the potential
of probiotics for the protection against H. pylori colonization as well as in the regulation of the
associated inflammation.
We have carried out studies to evaluate the ability of probiotics to protect against H. pylori infection
using mainly the strain L. fermentum UCO-979C. This probiotic strain was selected between other
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of lactic acid bacteria isolated from human gastric tissue because of its remarkable anti-H. pylori
properties [41]. The UCO-979C strain strongly inhibited the adhesion, growth and urease activity
of H. pylori in AGS cells and Mongolian gerbils [16,42]. Moreover, L. fermentum UCO-979C was able
to beneficially modulate the cytokine response of AGS cells and THP-1 macrophages after H. pylori
challenge [17]. Here, we extend those previous findings by demonstrating, for the first time, the ability
of L. fermentum UCO-979C to beneficially modulate the innate immune response triggered by H. pylori
in vivo.
Cytokines variations during the H. pylori infection have a significant impact on the evolution of
the gastric pathology due to their vast and pleiothropic e↵ects on immune and epithelial cells [43].
The increased production of proinflammatory cytokines and chemokines, including TNF-↵, IL-6,
IL-8 and MCP-1, during H. pylori gastric mucosal inflammation, has been well documented. Those
inflammatory factors can be secreted by gastric epithelial cells and play a major role in triggering the
mucosal inflammatory damage caused by H. pylori [44,45]. In addition, H. pylori and its virulence
factors are capable of increasing the production of the inflammatory mediators TNF-↵, IL-6, and IFN- 
by macrophages, which contribute to the amplification of the inflammatory response in the gastric
mucosa [46,47]. In our previous study [17], we demonstrated that L. fermentum UCO-979C significantly
reduced the production of IL-8, TNF-↵, IL-6, and MCP-1 in AGS cells and macrophages challenged
with H. pylori. The results presented here confirm those in vitro findings, by demonstrating that
the UCO-979C strain reduced the levels of TNF-↵, IL-8, and MCP-1 in the gastric mucosa of H.
pylori-infected mice. In addition, our previous in vitro studies also revealed the ability of the UCO-979C
strain to improve the levels of IL-10 in H. pylori-infected macrophages [17], which is in line with
the increased concentrations of IL-10 found in gastric and serum samples of H. pylori-infected mice.
Increased levels of IL-10 may contribute to the chronicity of gastritis, however, this regulatory cytokine
is of fundamental importance to prevent mucosal injury mediated by the inflammatory response [47–50].
Then, the balance in the inflammatory and regulatory cytokine production induced by L. fermentum
UCO-979C could o↵er advantages in the protection against H. pylori infection, since a reduced
inflammatory damage was observed in the histopathological analysis of gastric samples of mice.
The di↵erential cytokine profile induced by L. fermentum UCO-979C treatment in H. pylori-infected
mice could also explain the reduction in the pathogen gastric colonization. The generation of a Th1
response with the subsequent increase in the mucosal and systemic levels of IFN-  have been described
in both experimental animal models and human clinical trials [51,52]. The production of appropriate
levels of IFN-  has been associated to the protection against H. pylori infection. Peek et al. [53]
demonstrated that mice that are deficient in IFN-  have an increased susceptibility to H. pylori
colonization. It was also reported that the virulence factor cytotoxin-associated gene A (cagA) can be
translocated into the cytoplasm of dendritic cells, reducing the secretion of IL-12p40 and impairing
the generation of the Th1 response, which would favor the replication of H. pylori [54,55]. Then,
the increase in gastric IFN-  induced by probiotics such as L. fermentum UCO-979C could reduce the
initial replication of H. pylori in the initial steps of the infection.
Some studies have demonstrated that probiotic strains may exert beneficial e↵ects on H. pylori
infection and inflammation through the molecules produced and secreted by bacterial cells [56].
Interestingly, it was reported that L. rhamnosus GG-conditioned media was able to antagonize TNF-↵
secretion induced by H. pylori or LPS in murine macrophages [57]. In addition, the supernatant of L.
plantarum B7 administered to rats infected with H. pylori showed the ability to reduce gastric pathology
and apoptotic cells rate, as well as to decrease serum TNF-↵ and MDA levels [58]. Among the functional
molecules produced by probiotics, are EPSs macromolecules, which were proposed to be involved
in host–microbe interactions [59]. In that regard, a polysaccharide produced by Bacteroides fragilis
can suppress IL-17 and increase IL-10 production by intestinal immune cells and in a rodent model
of Helicobacter hepaticus infection [60]. In addition, it was described that polysaccharides produced
by L. salivarius B37 and L. salivarius B60 suppressed H. pylori-induced IL-8 production and mRNA
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expression in gastric epithelial cells [61]. To our knowledge, no other studies have demonstrated the
anti-H. pylori inhibitory and immunomodulatory e↵ects of EPS obtained from a probiotic strain.
We have reported that L. fermentum UCO-979C produces large amount of EPS and is able to form
biofilms on AGS and Caco-2 cell lines, inhibiting the colonization by H. pylori by up to 80% [15]. Thus,
it was concluded that the EPS was a key molecule in the ability of L. fermentum UCO-979C to inhibit
H. pylori colonization. In this work, we hypothesized that UCO-979C EPS is also involved in the
immunomodulatory e↵ects of this probiotic strains in the context of H. pylori infection. We confirmed
that the UCO-979C EPS was capable of inducing a significant reduction in H. pylori adhesion (~30%)
to AGS cells, which was comparable with the inhibitory activity of viable L. fermentum UCO-979C
(~44%) reported previously [17]. In addition, the UCO-979C EPS was able to di↵erentially modulate
the cytokine profile of AGS and THP-1 cells in response to the challenge with H. pylori. Similar to
our previous studies with L. fermentum UCO-979C [17], the UCO-979C EPS reduced the production
of TNF-↵, IL-6 and IL-8 in H. pylori-infected AGS cells while it diminished the production of TNF-↵
in H. pylori-infected THP-1 cells. Moreover, the in vivo studies of this work demonstrated that both
L. fermentum UCO-979C and its EPS were able to reduce IL-8 and enhance IL-10 levels in the gastric
mucosa of infected mice. It should be noted, however, that the immunological changes induced by
UCO-979C EPS in our in vitro and in vivo experiments did not completely resemble those observed
for the viable UCO-979C strain. The UCO-979C EPS was not able to improve the levels of IFN-  in
infected mice, as observed for the viable bacterium. The lack of ability of UCO-979C EPS to increase
IFN-  could be related to its inability to reduce H. pylori counts in vivo. In this sense, it would be of
great value to evaluate alternative treatments with UCO-979C EPS, varying concentrations and periods
of administration, to conclusively rule out its ability to increase gastric IFN-  in vivo.
The molecular mechanisms by which L. fermentum UCO-979C or its EPS modulate the secretion
of inflammatory cytokines and chemokines in H. pylori-infected AGS cells are not known. Some
studies have described the ability of probiotic lactobacilli to di↵erentially modulate the expression of
inflammatory factors in gastric epithelial cells through the suppression of NF-B activation [39,62].
Recently, we described the ability of L. fermentum UCO-979C to modify the expression of negative
regulators of TLR4 signaling in intestinal epithelial cells [18]. The UCO-979C strain diminished the
expression of MKP-1 and Tollip in intestinal epithelial cells after the activation of TLR4, conducting the
down-regulation in the expression of inflammatory factors such as IL-8, CXCL9, CXCL10, CXCL11,
and C3. Then, it is tempting to speculate that L. fermentum UCO-979C or its EPS are able to interact with
pattern recognition receptors expressed in gastric epithelial cells, inducing the upregulation of negative
regulators and thereby modifying the activation of signaling pathways such as the NF-B pathway,
and reducing the production of inflammatory mediators. The detailed molecular investigation of this
hypothesis is an interesting topic for future research.
In order to evaluate whether the immunomodulatory e↵ects of L. fermentum UCO-979C or its EPS
in the context of H. pylori infection were a strain-specific property, the in vitro and in vivo experiments
conducted in this work were performed in comparison with a strain of the same species, which
is also able to produce EPS. Although CRL973 EPS was able to slightly reduce H. pylori adhesion
to AGS cells and diminish the production of IL-8 and TNF-↵ by the gastric epithelial cells in vitro,
neither the CRL973 strain nor its EPS were able to induce changes in H. pylori colonization or protect
against inflammatory damage in infected mice. Interestingly, CRL973 EPS was not able to induce any
significant e↵ect in the cytokine profiles of THP-1 cells or gastric samples of infected mice. These results
allow us to arrive at two conclusions. First, the modulation of immune cells (such as macrophages)
would be of great relevance to achieve an optimal protective e↵ect in vivo. This implies that the in vitro
selection and characterization of immunomodulatory bacteria or their functional molecules for their
application in the prevention of H. pylori infection should not only be limited to the use of epithelial
cells but also include specialized cells of the immune system. Secondly, our results indicate that the
EPS produced by L. fermentum UCO-979C would have unique functional characteristics that deserve
to be studied in depth. Chemical, structural, genetic and genomic studies comparing the EPS of the
Microorganisms 2020, 8, 479 16 of 20
UCO-979C and CRL973 strains as well as their ability to interact with di↵erent pattern recognition
receptors would be of great importance to advance the knowledge of the molecular mechanisms
involved in the e↵ect of beneficial microorganisms against H. pylori infection.
The stomach mucosa is protected against pathogenic microbes by the low gastric pH, the secretion
of antimicrobial peptides and mucins by epithelial cells [63], as well as by the presence of an associated
microbiota [64]. Disbyosis of gastric microbiota and ine cient production of antimicrobial peptides
such as  -defensins have been implicated in an increased susceptibility to H. pylori infection [63,64].
Taking into consideration that the probiotic strain L. fermentum UCO-979C was originally isolated
from the healthy human gastric mucosa, it would be of value to investigate its influence on the gastric
microbiota, the production of antimicrobial peptides as well as the interaction among them, to further
characterize the mechanisms involved in its beneficial e↵ects.
In conclusion, this work demonstrates for the first time the in vivo ability of the probiotic
strain L. fermentum UCO-979C to improve the resistance against H. pylori infection by modulating
the gastric innate immune response. In addition, our results demonstrate that the EPS expressed
by L. fermentum UCO-979C is partially responsible for its immunomodulatory e↵ect, impacting its
anti-inflammatory activity.
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